Are We Reaching the End of the Line for PBM Exclusion Lists?

In the rapidly evolving U.S. healthcare landscape, the pharmacy benefit manager (PBM) exclusion lists ...

Common Pitfalls to Avoid to Ensure a Successful Product Launch

After spending millions on R&D just to get a product to market—and millions more ...

What Trump’s Win Might Mean for Pharma

First, let’s acknowledge the obvious—nobody knows what Trump’s win might mean for the pharma ...

The Promise and Threat of Biosimilars

The number of biologics available in the U.S. has grown every year for the ...

The Value Crisis in Pharma

The core of pharmaceutical marketing has expanded from efficacy and safety to include value. ...

Maximize Your Brand’s Value Post Patent Expiration Through Authorized Generics

In today’s marketplace, biopharmaceutical companies face numerous challenges from cost containment to patent expiration.1 ...

Novartis Strikes Pay-for-Performance Deals for Heart-Failure Drug Entresto

When Novartis’ new heart-failure treatment Entresto was approved in July, the pharmaceutical company said ...

Don’t Believe What PBMs Are Saying—The Truth Behind Formulary Exclusion Lists

The two largest pharmacy benefit managers (PBMs), CVS Health and Express Scripts, promote their ...

Four Facts You Should Know About Oncology Pathways

Oncology pathways are detailed, evidence-based care processes that sometimes specify the single best treatment ...

Five Facts To Know About HEOR

The heat is on payers to identify which brands offer the best value, and ...

[sam_pro id=0_12 codes="true"]
[sam_pro id=0_6 codes="false"]